RETN encodes resistin, a proinflammatory adipocytokine primarily secreted by macrophages in humans 1. Resistin functions as a hormone that appears to suppress insulin's ability to stimulate glucose uptake in adipose cells and potentially links obesity to diabetes. The protein also promotes chemotaxis in myeloid cells and plays significant roles in immune responses. Recent research has revealed resistin's involvement in liver allograft rejection, where recipient-derived intermediate monocytes utilize the resistin-CAP1 signaling pathway to mediate T cell-mediated rejection reactions 2. Multiple polymorphisms in the RETN gene, particularly the -420C>G variant, have been associated with various disease susceptibilities including colon cancer 3, acne vulgaris 4, type 2 diabetes mellitus 5, and anorexia nervosa 6. The rs3219175 G>A polymorphism shows significant association with overall cancer risk 7. Computational analysis has identified several deleterious single nucleotide polymorphisms that may alter protein structure and function 1. Clinically, RETN expression correlates with cancer stage, survival prognosis, and immune infiltration in certain malignancies, suggesting its potential as both a prognostic marker and therapeutic target.